Alcohol dependence treatment accepted for NHS use

Nalmefene (Selincro) has been recommended by NICE as a possible treatment for reducing alcohol consumption in people with alcohol dependence.

In trials, nalmefene plus psychosocial support reduced alcohol consumption by 1.8 units per day compared with psychosocial support alone. | SCIENCE PHOTO LIBRARY
Nalmefene may be prescribed on the NHS for people who:
  • have a high drinking risk (defined as alcohol consumption of more than 60g (7.5 units) per day for men and more than 40g (5 units) per day for women, according to the World Health Organization's drinking risk levels) without physical withdrawal symptoms, and
  • who do not require immediate detoxification.

Nalmefene must be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption. It should only be started in patients who continue to have a high drinking risk 2 weeks after their initial assessment.

Nalmefene is an opioid receptor modulator which acts by reducing the urge to drink. One 18mg tablet is taken daily as needed, 1–2 hours before the patient believes he or she will be at risk of drinking.

NICE guidance on nalmefene for reducing alcohol consumption in people with alcohol dependence

Follow MIMS on Twitter

Sign up for MIMS bulletins

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

An empty tablet blister pack.

Ezetimibe supply update

Availability issues have been reported for the lipid-lowering...

Woman holding blister strip of contraceptive pills

Pharmacists across England to initiate oral contraceptives

Pharmacy Contraception Service (PCS) could allow almost...